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Abstract 
Background: Chronic radicular pain is often treated by epidural steroid 
infiltration (ESI). In 2014, the Food and Drug Administration (FDA) issued a 
letter warning that ESI may result in rare but serious adverse events, including 
“loss of vision, stroke, paralysis, and death”. In this retrospective study, we 
compare retrolaminar paravertebral infiltration (PVI) of a non-steroid-mixture 
with an epidural steroid injection (ESI). 
Materials and Methods: We identified 31 patients registered in the Quebec 
Pain Registry suffering from chronic lumbar or cervical radicular pain 
referred to the Centre Hospitalier de l’Université de Montréal (CHUM) pain 
clinic between 2009 to 2014. These patients received ultrasound-guided 
retrolaminar PVI with a mixture of morphine 1 mg, ketamine 10 mg,  
neostigmine 0.5 mg, naloxone 2ng, and bupivacaine 10 mg. The control 
group, matched for gender, age, and DN4 sub-scale score at baseline, 
consisted of 31 patients with the same pathology; they were treated by 
fluoroscopic-guided ESI. Principal pathologies in both groups were disc 
disorders and/or foraminal stenosis. All patients received only one infiltration 
during the six months following the initial visit. The numerical rating scale 
(NRS-11) was assessed at the first visit and six months later. The BPI, PCS 
and SF-12 were compared in both groups. Overall satisfaction with pain relief 
after six months was assessed with a scale of 1 (very unsatisfied) to 6 (very 
satisfied). 
Results: Average NRS-11 scores for the seven days preceding the first visit 
and after six months were compared in both groups. The same comparison 
was made for overal1 treatment satisfaction. There is no significant 
difference in the NRS-11 and in the satisfaction scores between the two 
groups. 
Conclusion: Neither of the two methods was shown to be superior to the 
other in pain relief and overall treatment satisfaction after six months. 
Considering the possible complications and side effects of ESI, PVI with a 
non-steroid mixture might be considered as an alternative method. Possibly, 
multiple PVIs could further decrease pain. Well-designed studies are needed 
to evaluate this hypothesis. 
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Introduction 
The first therapeutic epidural injection was 
performed in 1885 by neurologist James Leonard 
Corning by injecting the local anesthetic cocaine 
between the lower lumbar spinous processes. The first 
modern controlled trial evaluating epidural steroid 
injection (ESI) was performed by Swerdlow et al. in 
1970. ESIs are the most widely used pain 
management procedures in the world. Their use is 
supported by many placebo-controlled studies and 
dozens of systematic reviews. Despite the extensive 
literature on the subject, there continues to be 
considerable controversy surrounding the safety and 
efficacy of this procedure (1).  
ESI is the most frequently performed 
procedure in pain clinics throughout the United 
States, more than doubling between 2000 and 2008 
(2). It is estimated that the annual cost to treat back 
pain alone exceeds $100 billion (3). However, on 
April 23, 2014, the Food and Drug Administration 
(FDA) issued a drug safety communication warning 
that the injection of corticosteroids into the epidural 
space of the spine may result in rare but serious 
adverse events and required  label changes to warn of 
rare, but serious neurological problems (4). Specific 
events reported include, but are not limited to, spinal 
cord infarction, paraplegia, quadriplegia, cortical 
blindness, and stroke. This warning resulted from a 
rapidly expanding body of the literature illustrating 
the potential for catastrophic neurological 
complications, including brain and spinal cord 
infarction following the intra-arterial injection of 
corticosteroids.  
However, all experts did not accept this 
warning, and there is a debate regarding the risk-
benefit of ESI (5). This controversy, along with the 
lack of sufficient supporting documents showing the 
ESI as an effective treatment in low back pain 
syndromes, caused us to consider other possible 
interventions with different medications. The purpose 
of this study is to compare the effectiveness of 
ultrasound-guided retrolaminar PVI with a non-
steroid containing mixture versus ESI in patients 
suffering from chronic cervical or lumbar radicular 
neuropathic pain. 
Methods 
We identified two groups of 31 patients 
registered in Quebec Pain Registry data bank 
suffering from chronic lumbar or cervical radicular 
pain who were referred to the pain clinic between 
2009 to 2014. Informed consent was obtained from all 
the patients. All the patients were 18 to 75 years old. 
The primary cause of the pain was a disc herniation or 
foraminal stenosis. The neuropathic nature of the pain 
was diagnosed based on the DN4≥4. All cases with 
malignancies, congenital anomalies, infection, motor 
or sensory neurological diseases, cognitive 
impairment, alcohol, or illicit drug dependence, and 
past history of lumbar or cervical operations were 
excluded. All patients were evaluated at the initial 
visit in the pain clinic and six months later. The 
patients received only one infiltration during the six 
months following the initial visit. The data were 
collected in forms completed by patients and/or a 
research nurse. Pain intensity was assessed at the first 
visit and at the six-month follow-up using a numerical 
rating scale (NRS-11). The BPI, PCS and SF-12 were 
compared in both groups. Overall satisfaction with 
pain relief over the six months was assessed with a 
scale of 1 (very unsatisfied) to 6 (very satisfied) 
(Statistical analysis software SAS version 9.3). 
Using a Broad-spectrum convex transducer 
(C1-5-D), the case group received an ultrasound-
guided (LOGIQ e, GE Healthcare, Milwaukee, WI) 
retrolaminar PVI with a mixture of morphine 1 mg, 
ketamine 10 mg, neostigmine 0.5 mg, naloxone 2 ng, 
and bupivacaine 10 mg. The vertebral laminae were 
identified by ultrasound imaging in a paramedian 
sagittal plane by sequentially visualizing transverse 
processes and the corresponding laminae (from lateral 
to medial). After local anesthesia with lidocaine 2%, 
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the block needle (BD spinal needle Quincke 25 G) 
was guided to contact the lamina, and the mixture 
injected was visualized under real-time imaging. The 
injection was done in the laminae adjacent to the root, 
which corresponds clinically and radiologically to 
radicular pain. Radiological images were verified for 
possible anatomical variations (such as lumbarization 
of S1 or sacralization of L5). The control group, 
matched for gender, age, and DN4 sub-scale score at 
baseline, consisted of 31 patients with the same 
pathology, pain, and period who were treated by ESI 
(interlaminar or foraminal) under fluoroscopic 
control. 
Results 
Average NRS-11 scores for seven days 
preceding the first visit were 7.5 (SD=1.7) and 7.2 
(SD=1.9) in the case and the control groups, 
respectively. At the six-month follow-up visit, these 
scores were 6.9 (SD=1.9) and 6.2 (SD=2.4), 
respectively (Figure 1). No significant changes were 
noted in NRS-11 scores at the six-month visit 
between two groups. Overal1 satisfaction from pain 
relief at six months was 3.8 (SD=1.8) and 4.5 
(SD=1.5) in the case and the control group, 
respectively (Figure 2). There was no significant 
difference in satisfaction score between the two 
groups. 
Discussion 
Based on the Crow W et al. study, it is 
estimated that the annual cost to treat back pain alone 
exceeds $100 billion (3). Among those who develop 
low back pain, approximately 30% will develop either 
chronic pain or frequent recurrences. Neck pain is less 
well-publicized, but also exacts a steep 
socioeconomic toll. Nearly two thirds of patients will 
experience a significant episode of neck pain over the 
course of their lives, with the annual prevalence 
around 30%. 
ESI could be considered as the most frequently 
performed procedures in pain clinics in the United 
States, and by some estimates, its use has doubled 
between 2000 and 2008 (2). Although this procedure 
has historically been utilized for spinal pain of all 
types, ESI is widely acknowledged to work better for 
neuropathic pain. However, there continues to be 
enormous controversy surrounding the short- and 
long-term effectiveness and, more recently, safety of 
this treatment (4, 5). The mechanisms by which 
steroids produce their analgesic effects have been a 
subject of debate. Inhibition of phospholipase A2 as 
an inflammatory mediator by itself (6) and as a rate-
limiting factor involved in the production of 
eicosanoids (prostaglandins, prostacyclins, 
thromboxanes, and leukotrienes) could be the 
mechanisms of action. Steroids may inhibit pain via 
their ability to suppress ectopic discharges from 
 
Figure 1.Average NRS-11scores for the seven days 
preceding the first visit and at the six-month follow-up 
visit in the case and in the control groups (NRS-11: 
numerical rating scale). 
 
Figure 2. Overal1 satisfaction from pain relief at the six-
month follow-up visit in the case and in the control 
groups. 
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injured nerve fibers (7) and depress conduction in 
normal unmyelinated C fibers. Other than the steroid 
effect, local anesthetics act via their increasing the 
blood flow in the ischemic nerves (8), suppressing 
ectopic discharges from injured neurons, slowing or 
halting nociceptive transmission (9), and the washout 
effect of the injected volume. There is increasing 
interest in the medical community in finding 
alternative approaches to treat back pain. First of all, 
retrolaminar paraspinal space could be considered as 
an alternative site for injection.  
The thoracic paravertebral (TPV) nerve block 
technique was first described more than one century 
ago and reintroduced into clinical practice by Eason 
and Wyatt in 1978. Recently, there have been 
numerous reports concerning the use of an ultrasound 
guided paravertebral block. Interestingly, some 
authors have used ultrasound-guided retrolaminar 
technique (Figure 3) to infiltrate or to place the 
catheter (10). The concept that local anesthetic can 
penetrate the paravertebral space from a laminar 
injection challenges the classical teaching that the 
paravertebral space is defined posteriorly as a closed 
space by the costotransverse ligament. It is possible 
that the medication trickles through the medial 
aperture of the superior costotransverse ligament 
where the dorsal ramus of the spinal nerve exits 
posteriorly to innervate the paraspinal muscles. It is 
also possible that the fluid tracks anteriorly through 
the loose tissues just lateral to the facet joints. The 
same concept could be considered to explain the 
diffusion of solution from the retrolaminar space to 
nerve roots in lumbar and cervical PVI. Moreover, the 
boundary of the TPV space in the caudal direction is 
subject to debate. Although some cadaver studies 
showed that the caudal end of the T12 TPV space is 
effectively sealed off by the origin of the psoas major 
muscle, other studies observed communication 
between thoracic and lumbar paravertebral space (11). 
The feasibility of lumbar spine sonography has 
been reviewed by Darrieutort-Laffite et al. In the 
cervical spine, Saranteas et al. examined the 
ultrasound anatomy of the cervical paravertebral 
space in 20 volunteers (12). They found that there was 
an excellent visualization of the C3, C4, C5, C6, and 
C7 transverse processes in all cases. The C5, C6, and 
C7 nerve roots were excellently identified in all cases. 
In the present study, all patients with cervical 
paravertebral infiltration received infiltration between 
C5 and C7.  
The drug mixture we used consisted of 
morphine, ketamine, neostigmine, naloxone, and 
bupivacaine. In acute and chronic pain setting, 
morphine or its related family members are widely 
used. Its presynaptic and postsynaptic effects are via 
G-protein-linked opioid mu (mainly), delta, and kappa 
receptors. Presynaptic interaction inhibits the release 
of substance-P and calcitonin gene-related peptide by 
means of interactions with N-type voltage-dependent 
calcium channels and reduced calcium influx. 
Postsynaptic activation of opioid receptors leads to 
inhibition of adenylate-cyclase and also results in the 
opening of potassium channels, which in turn causes 
hyperpolarization, rendering the postsynaptic second-
order neuron less responsive. Opioid receptors are 
expressed by central and peripheral neurons as well as 
by neuroendocrine (pituitary, adrenal), immune, and 
ectodermal cells (13). So morphine, which is used in 
the case group, might produce its analgesic effects via 
penetrating the epidural space and acting centrally 
and/or peripherally through an anti-inflammatory and 
analgesic effect on the peripheral nerves in the 
foraminal area. 
Local anesthetics are primarily characterized 
by their ability to block voltage-gated sodium 
 
Figure 3. Schematic comparison of the retrolaminar and 
classic techniques of paravertebral blockade showing a 
transverse section of the vertebra. 
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channels. In addition, to sodium channel blockade, 
local anesthetics also interact with a wide array of 
alternative target structures, for example tetrodotoxin-
resistant sodium channels, potassium channels, 
calcium channels, N-methyl-D-aspartate (NMDA) 
receptors, and G-protein coupled receptors (14). Other 
than blocking neural transmission, bupivacaine may 
possibly cause its analgesic effects in chronic pain via 
the other receptors and mechanisms. 
Naloxone is an opioid mu-receptor competitive 
antagonist. In low doses (in fact, in “ultra-low 
doses”); it helps control pain and prevents 
hyperalgesia. A review of the literature suggests that 
under certain conditions, low-dose opioid antagonists 
(alone or in combination with opioids) can produce an 
antinociceptive or analgesic response (15). 
Furthermore, they have been used successfully in 
Crohn’s disease and irritable bowel syndrome (IBS) 
to control disease-associated pain. The possible 
mechanisms of action might be upregulation of opioid 
receptors, increased levels of endogenous opioids, 
decreased opioid receptor coupling to stimulatory G-
proteins (mediated through filament A), and an 
inhibition of opioid agonist-induced activation of glial 
cells (15). In a case report, adding 50 ng/day naloxone 
to the intrathecal morphine infusion dramatically 
enhanced the analgesic effect of morphine without 
apparent side effects for more than three years (16). 
These mechanisms can explain partly the analgesic 
role of the naloxone in the mixture. The mechanistic 
rationale for the naloxone/morphine dose and 
concentration ratio was based on animal studies and a 
case report (16) in which an IT naloxone/morphine 
concentration ratio of 1/10
5
 was efficient in 
controlling the pain for three years.  
Ketamine is an intravenous anesthetic which 
has an analgesic effect in sub-anesthetic doses. In a 
review article, De Kock et al. (17) reviewed the effect 
of ketamine on the inflammatory process. They 
concluded that ketamine is an immunomodulator that 
prevents the exacerbation and the extension of local 
inflammation without blunting the local process and 
delaying inflammatory resolution. It has an anti-
hyperalgesic effect due to its impact on NMDA 
receptors (18) and an anti-allodynic effect by 
suppressing toll-like receptor (TLR) mediated signal 
transduction (19). Ketamine possesses a plethora of 
other actions that enhance its analgesic properties. 
These include blocking non-NMDA glutamate and 
muscarinic cholinergic receptors, facilitating GABA-
A signaling, weakly binding to opioid receptors, and 
possessing local anesthetics as well as possibly 
neuroregenerative properties (20). Ketamine shows 
anti-inflammatory (17), antidepressant (21), 
precognitive (17) effects, as well as a beneficial effect 
on respiration, which can counter the side effects of 
morphine. Moreover, the beneficial effects of 
ketamine in the inflammatory process and post-
operative outcome should not be neglected.  
Neostigmine was introduced in 1931. It is a 
reversible inhibitor of the enzyme cholinesterase, 
which results in an increased concentration of the 
acetylcholine neurotransmitter. However, due to its 
hydrophilic nature (presence of a functional 
quaternary ammonia), it does not cross the dura 
mater. In 1933, Pellandra reported that intravenous 
administration of the anticholinesterase drug 
physostigmine produced analgesia in human beings. 
Neostigmine has been tested by the intrathecal (22), 
epidural (23), intra-articular (23), and intravenous 
(24) approaches to control pain. The analgesia 
resulting from spinal administration of neostigmine 
may be due to the increased concentration of 
acetylcholine and the consequent binding to 
muscarinic and nicotinic receptors. Epidural 
neostigmine analgesia seems to be a result of the 
more central rather than peripheral action. In a study 
by Laurreti GR et al. (23) in patients undergoing knee 
surgery, epidural neostigmine resulted in analgesia 
after the administration of a ten-fold lower dose (1 
μg/kg) when compared to knee intra-articular 
administration, suggesting a central effect. 
Acetylcholine receptor activation in peripheral nerves 
is associated with analgesia (25), and intra-articular 
neostigmine seems to relieve pain after knee 
arthroscopy. Based on all these mechanisms, it could 
be hypothesized that neostigmine in the mixture could 
exert its analgesic effects by spreading on the dorsal 
root and probably in the epidural space. Due to very 
low doses of the drugs (especially the ultra-low dose 
of naloxone), absorption and systemic effects could 
not be an important factor in the long-term analgesic 
effect of the mixture. 
The pain scores were relatively high in both 
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groups after six months. The score was only taken 
once by phone six months after the initial referral to 
the pain clinic. This score shows the average pain 
during the seven days before contact, but it does not 
show the intensity of pain in the days following 
injection. Overal1 satisfaction from pain relief is 
relatively high in both groups. So it can be concluded 
that the pain management service (including epidural 
or retrolaminar PVI) after six months had a positive 
impact on the pain intensity. Interestingly, there is no 
significant difference between two groups. However, 
there are the other limitations in this study such as: 
patient heterogeneity, the multicentric nature of the 
study, only one infiltration over six months, and 
missing information concerning pain relief in the days 
following infiltration.  
Conclusion 
In order to better understand the outcome of 
patients treated via retrolaminar PVI using a new 
mixture, studies need to be undertaken involving a 
greater number of patients and randomized trials. It 
would be preferable to study a mixture of two or three 
drugs instead of five drugs as in the current study; the 
impact on pain and quality of life should then be 
evaluated at more frequent intervals. However, based 
on the FDA warning concerning ESI and the debate 
surrounding it, finding new approaches and 
medications for the treatment of spinal radicular pain 
is an important challenge that needs to be addressed 
in future studies. This study shows the possibility of 
using drugs other than steroids in paraspinal 
interventions. 
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